Western blot analysis revealed that gefitinib consistently induced BIM in all three NSCLC lines expressing mutant EGFR. The level of BIM induction was higher in the H3255 and HCC827 cells, in accordance with their greater sensitivity to apoptosis than the H1650 cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.